Literature DB >> 26037279

Blood and tissue neuroendocrine tumor gene cluster analysis correlate, define hallmarks and predict disease status.

Mark Kidd1, Ignat Drozdov1, Irvin Modlin2.   

Abstract

A multianalyte algorithmic assay (MAAA) identifies circulating neuroendocrine tumor (NET) transcripts (n=51) with a sensitivity/specificity of 98%/97%. We evaluated whether blood measurements correlated with tumor tissue transcript analysis. The latter were segregated into gene clusters (GC) that defined clinical 'hallmarks' of neoplasia. A MAAA/cluster integrated algorithm (CIA) was developed as a predictive activity index to define tumor behavior and outcome. We evaluated three groups. Group 1: publically available NET transcriptome databases (n=15; GeneProfiler). Group 2: prospectively collected tumors and matched blood samples (n=22; qRT-PCR). Group 3: prospective clinical blood samples, n=159: stable disease (SD): n=111 and progressive disease (PD): n=48. Regulatory network analysis, linear modeling, principal component analysis (PCA), and receiver operating characteristic analyses were used to delineate neoplasia 'hallmarks' and assess GC predictive utility. Our results demonstrated: group 1: NET transcriptomes identified (92%) genes elevated. Group 2: 98% genes elevated by qPCR (fold change >2, P<0.05). Correlation analysis of matched blood/tumor was highly significant (R(2)=0.7, P<0.0001), and 58% of genes defined nine omic clusters (SSTRome, proliferome, signalome, metabolome, secretome, epigenome, plurome, and apoptome). Group 3: six clusters (SSTRome, proliferome, metabolome, secretome, epigenome, and plurome) differentiated SD from PD (area under the curve (AUC)=0.81). Integration with blood-algorithm amplified the AUC to 0.92±0.02 for differentiating PD and SD. The CIA defined a significantly lower SD score (34.1±2.6%) than in PD (84±2.8%, P<0.0001). In conclusion, circulating transcripts measurements reflect NET tissue values. Integration of biologically relevant GC differentiate SD from PD. Combination of GC data with the blood-algorithm predicted disease status in >92%. Blood transcript measurement predicts NET activity.
© 2015 Society for Endocrinology.

Entities:  

Keywords:  Ki-67; NET; PCR; algorithm; biomarker; carcinoid; gastroenteropancreatic; hallmarks; multigene transcript; neuroendocrine; proliferation

Mesh:

Substances:

Year:  2015        PMID: 26037279     DOI: 10.1530/ERC-15-0092

Source DB:  PubMed          Journal:  Endocr Relat Cancer        ISSN: 1351-0088            Impact factor:   5.678


  34 in total

Review 1.  Pancreatic neuroendocrine tumors: A review of serum biomarkers, staging, and management.

Authors:  Zu-Yi Ma; Yuan-Feng Gong; Hong-Kai Zhuang; Zi-Xuan Zhou; Shan-Zhou Huang; Yi-Ping Zou; Bo-Wen Huang; Zhong-Hai Sun; Chuan-Zhao Zhang; Yun-Qiang Tang; Bao-Hua Hou
Journal:  World J Gastroenterol       Date:  2020-05-21       Impact factor: 5.742

Review 2.  Clinical applications of (epi)genetics in gastroenteropancreatic neuroendocrine neoplasms: Moving towards liquid biopsies.

Authors:  Gitta Boons; Timon Vandamme; Marc Peeters; Guy Van Camp; Ken Op de Beeck
Journal:  Rev Endocr Metab Disord       Date:  2019-09       Impact factor: 6.514

Review 3.  Towards a new classification of gastroenteropancreatic neuroendocrine neoplasms.

Authors:  Mark Kidd; Irvin Modlin; Kjell Öberg
Journal:  Nat Rev Clin Oncol       Date:  2016-06-07       Impact factor: 66.675

4.  Therapy: The role of liquid biopsies to manage and predict PRRT for NETs.

Authors:  Mark Kidd; Irvin M Modlin
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2017-03-15       Impact factor: 46.802

Review 5.  Histopathological, immunohistochemical, genetic and molecular markers of neuroendocrine neoplasms.

Authors:  Georgios Kyriakopoulos; Vasiliki Mavroeidi; Eleftherios Chatzellis; Gregory A Kaltsas; Krystallenia I Alexandraki
Journal:  Ann Transl Med       Date:  2018-06

Review 6.  Molecular strategies in the management of bronchopulmonary and thymic neuroendocrine neoplasms.

Authors:  Irvin M Modlin; Mark Kidd; Pier-Luigi Filosso; Matteo Roffinella; Anna Lewczuk; Jaroslaw Cwikla; Lisa Bodei; Agnieska Kolasinska-Cwikla; Kyung-Min Chung; Margot E Tesselaar; Ignat A Drozdov
Journal:  J Thorac Dis       Date:  2017-11       Impact factor: 2.895

Review 7.  Translational research in neuroendocrine tumors: pitfalls and opportunities.

Authors:  J Capdevila; O Casanovas; R Salazar; D Castellano; A Segura; P Fuster; J Aller; R García-Carbonero; P Jimenez-Fonseca; E Grande; J P Castaño
Journal:  Oncogene       Date:  2016-09-19       Impact factor: 9.867

8.  Assessment of NETest Clinical Utility in a U.S. Registry-Based Study.

Authors:  Eric Liu; Scott Paulson; Anthony Gulati; Jon Freudman; William Grosh; Sheldon Kafer; Prasanna C Wickremesinghe; Ronald R Salem; Lisa Bodei
Journal:  Oncologist       Date:  2018-08-29

Review 9.  Neuroendocrine neoplasia of the gastrointestinal tract revisited: towards precision medicine.

Authors:  Guido Rindi; Bertram Wiedenmann
Journal:  Nat Rev Endocrinol       Date:  2020-08-24       Impact factor: 43.330

10.  Measurement of circulating transcripts and gene cluster analysis predicts and defines therapeutic efficacy of peptide receptor radionuclide therapy (PRRT) in neuroendocrine tumors.

Authors:  L Bodei; M Kidd; I M Modlin; S Severi; I Drozdov; S Nicolini; D J Kwekkeboom; E P Krenning; R P Baum; G Paganelli
Journal:  Eur J Nucl Med Mol Imaging       Date:  2015-11-23       Impact factor: 9.236

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.